

## Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam

*First Patient Dosed in Study Evaluating Mitazalimab in Combination with Cancer Vaccine for Patients with Pancreatic Cancer*

**Lund, Sweden, November 8, 2021** – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation of a proof-of-concept Phase Ib clinical trial to assess the safety and efficacy of mitazalimab in combination with MesoPher, an experimental dendritic cell vaccine, in patients with pancreatic cancer. The trial will be led by investigators at Erasmus MC University Medical Center Rotterdam, The Netherlands.

The first patient has been dosed in the phase I proof-of-concept study trial, REACTiVe-2, that will enroll up to 18 patients with pancreatic cancer. REACTiVe-2 will assess the safety and efficacy of Alligator's second generation CD40 agonist, mitazalimab in combination with the investigational cancer vaccine MesoPher, which is comprised of autologous dendritic cells loaded with allogeneic tumor lysate (PheraLys), in patients with progressive metastatic pancreatic cancer. Mitazalimab is currently in Phase II trial in pancreatic cancer patients in combination with chemotherapy. MesoPher, under development by Amphera B.V., is currently in a Phase III trial in mesothelioma and a phase II trial in pancreatic cancer. The investigator sponsored trial, REACTiVe-2, will be performed at Erasmus MC University Medical Center Rotterdam.

The clinical study is supported by strong preclinical data that was recently published in the high-ranking peer-reviewed journal "Journal of Immunotherapy of cancer" (Lau SP, *et al.* J Immunother Cancer 2020). This study demonstrates that CD40 agonists in combination with dendritic cells loaded with allogeneic tumor lysate mediates powerful and significant anti-tumor effects in pancreatic cancer models.

"This new trial is an important step forward in expanding the potential of mitazalimab in a patient population with high medical needs," said Alligator's CEO, Søren Bregenholt. "Erasmus MC University Medical Center Rotterdam is the ideal partner for the clinical evaluation of mitazalimab's ability to enhance the response of a promising cancer vaccine in pancreatic cancer."

**For further information, please contact:**

Julie Silber, Investor Relations

Phone: +46 46-540 82 23

E-mail: [jur@alligatorbioscience.com](mailto:jur@alligatorbioscience.com)

**About Alligator Bioscience**

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit <http://www.alligatorbioscience.com>.